Version May 2024
Short corneal or conjunctival procedures, ophthalmic anesthesia: Ophthalmic: Instill 2 drops of 0.5% solution 30 seconds prior to procedure; a crossover study in 22 premature neonates (GA: <30 weeks) undergoing examination for retinopathy of prematurity showed decreased pain scores compared to placebo (Ref).
Short corneal or conjunctival procedures: Infants, Children, and Adolescents: Ophthalmic: Instill 1 drop of 0.5% solution in eye every 5 to 10 minutes for 5 to 7 doses
Tonometry, gonioscopy, suture removal: Infants, Children, and Adolescents: Ophthalmic: Instill 1 to 2 drops of 0.5% solution in eye just prior to procedure
There are no dosage adjustments provided in manufacturer's labeling.
There are no dosage adjustments provided in manufacturer's labeling.
(For additional information see "Proparacaine: Drug information")
Anesthesia, ocular:
Short corneal and conjunctival procedures: Ophthalmic: Instill 1 drop in eye(s) every 5 to 10 minutes for 5 to 7 doses.
Tonometry, gonioscopy, suture removal: Ophthalmic: Instill 1 to 2 drops in eye(s) just prior to procedure.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Dermatologic: Allergic contact dermatitis
Hypersensitivity: Hypersensitivity reaction (corneal; characterized by acute, intense, and diffuse epithelial keratitis; gray, ground glass appearance; exfoliation of skin; corneal filaments; and can include iritis with descemetitis)
Ophthalmic: Burning sensation of eyes, conjunctival hemorrhage, conjunctival hyperemia, corneal erosion, cycloplegia, eye redness, mydriasis, stinging of eyes
Hypersensitivity to proparacaine or any component of the formulation
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only; prolonged use may result in permanent corneal opacification and visual loss and is not recommended.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as hydrochloride:
Alcaine: 0.5% (15 mL) [contains benzalkonium chloride]
Generic: 0.5% (15 mL)
Yes
Solution (Alcaine Ophthalmic)
0.5% (per mL): $3.27
Solution (Proparacaine HCl Ophthalmic)
0.5% (per mL): $2.81 - $2.93
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
For ophthalmic use only. Do not use if discolored; protect eye from irritating chemicals, foreign bodies, and blink reflex; use eye patch if necessary.
Ophthalmic: Instill drops into affected eye(s); avoid contact of bottle tip with skin or eye
Ophthalmic: For topical ophthalmic use only. To be administered by health care provider; not for patient self-administration. Do not use if discolored (darker than clear to straw color); protect eye from irritating chemicals, foreign bodies, and blink reflex; use eye patch if necessary. To avoid contamination, do not touch dropper tip to eyelids or any surface.
Store under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light.
Local anesthesia for tonometry, gonioscopy; suture removal from cornea; removal of corneal foreign body; cataract extraction, glaucoma surgery; short operative procedure involving the cornea and conjunctiva (FDA approved in all ages)
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy
Animal reproduction studies have not been conducted.
Prevents initiation and transmission of impulse at the nerve cell membrane by decreasing ion permeability through stabilizing
Onset of action: Within 20 seconds of instillation
Duration: ~10 to 20 minutes
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
